TGFB1 and neoplasm: Mariathasan and colleagues showed that TGF-β1-neutralising mAbs can promote lymphocyte infiltration into tumours and improve response to αPD-L1 immunotherapy.2 In our CAF-rich models, we similarly found that TGF-β1 inhibition increases intratumoural CD8 T-cell density.